A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 510 participants.

Also called NCT06559722

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 510 participants (planned count) (from the registry)
Sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd (from the registry)
Registry
  • NCT NCT06559722
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06559722. Randomized; no masking; primary purpose treatment. Start 2024-08 (anticipated); primary completion 2025-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Intervention (Drug)
Insulin Degludec/liraglutide Injection
Intervention (Drug)
XULTOPHY®
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd (class: industry)

Record details

Record id
cardio:ct-nct06559722
Content hash
1dbbf00b6e571c881c2438c0869d146e7f1b6a71dc873c16a6d6e7ac229b3244